Specialty Pharmacy News Roundup: March 2024

The latest specialty pharmacy news and insights. Stay up to date on industry and company trends with Specialty Pharmacy Database and client-specific research. 


CarepathRx, a leader in pharmacy and medication management solutions, announced the launch of its groundbreaking mobile application, CarepathRx Patient Therapy Mobile (CPTM). This innovative app is designed to empower both specialty and traditional patients in managing their prescriptions effectively from the convenience of their smartphones. CPTM, a white-label product, allows pharmacies to brand the app as their own, offering a seamless extension of their services to their customers. This user-friendly app integrates directly with DromosPTM and the client’s Pharmacy Management System (PMS), enabling pharmacies to streamline their operations and enhance patient engagement. Through the industry’s most comprehensive, end-to-end hospital pharmacy care delivery model, CarepathRx is turning hospital pharmacy into an active care management strategy and revenue generator while providing support across the patient’s complete healthcare journey.


Madrigal Pharmaceuticals, Inc., a biopharmaceutical company focused on delivering novel therapeutics for nonalcoholic steatohepatitis (NASH), announced that the FDA has granted accelerated approval for Rezdiffra (resmetirom) in conjunction with diet and exercise for the treatment of adults with noncirrhotic NASH with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis). AllianceRx Walgreens Pharmacy, Amber Specialty Pharmacy, and Maxor Specialty have been selected as a limited distribution partners.


Merck, known as MSD outside of the United States and Canada, announced that the FDA approved sotatercept-csrk (WINREVAIR, for injection) for the treatment of adults with pulmonary arterial hypertension (PAH). WINREVAIR was previously granted Breakthrough Therapy Designation by the FDA. WINREVAIR is the first FDA-approved activin signaling inhibitor therapy for PAH, representing a new class of therapy that works by improving the balance between pro- and anti-proliferative signaling to regulate vascular cell proliferation underlying PAH. The company plans to make WINREVAIR available through select specialty pharmacies in the US by the end of April.


PromptCare has been selected by Kedrion Biopharma to dispense Coagadex, a limited-distribution therapy approved in 2015 by the U.S. Food and Drug Administration (FDA) for the treatment of factor X deficiency. Coagadex is the first and only FDA-approved therapy to treat hereditary factor X deficiency and is the only factor X concentrate available worldwide. PromptCare is a leading national provider of in-home and alternate-site infusion therapies and high-tech, hands-on respiratory services.